- Home
- ACAD vs MLCO Comparison
ACAD vs MLCO Comparison
Compare ACAD & MLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- MLCO
- Stock Information
- Founded
- ACAD 1993
- MLCO 2004
- Country
- ACAD United States
- MLCO Hong Kong
- Employees
- ACAD N/A
- MLCO N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- MLCO Hotels/Resorts
- Sector
- ACAD Health Care
- MLCO Consumer Discretionary
- Exchange
- ACAD Nasdaq
- MLCO Nasdaq
- Market Cap
- ACAD 3.5B
- MLCO 3.7B
- IPO Year
- ACAD 2004
- MLCO 2006
- Fundamental
- Price
- ACAD $21.09
- MLCO $7.99
- Analyst Decision
- ACAD Buy
- MLCO Buy
- Analyst Count
- ACAD 20
- MLCO 6
- Target Price
- ACAD $29.25
- MLCO $9.78
- AVG Volume (30 Days)
- ACAD 2.5M
- MLCO 2.8M
- Earning Date
- ACAD 11-05-2025
- MLCO 11-04-2025
- Dividend Yield
- ACAD N/A
- MLCO N/A
- EPS Growth
- ACAD 615.00
- MLCO N/A
- EPS
- ACAD 1.33
- MLCO 0.14
- Revenue
- ACAD $1,018,885,000.00
- MLCO $4,926,670,000.00
- Revenue This Year
- ACAD $14.01
- MLCO $12.85
- Revenue Next Year
- ACAD $11.81
- MLCO $3.61
- P/E Ratio
- ACAD $15.76
- MLCO $57.75
- Revenue Growth
- ACAD 14.41
- MLCO 12.41
- 52 Week Low
- ACAD $13.40
- MLCO $4.55
- 52 Week High
- ACAD $26.65
- MLCO $10.15
- Technical
- Relative Strength Index (RSI)
- ACAD 43.19
- MLCO 37.76
- Support Level
- ACAD $20.33
- MLCO $7.86
- Resistance Level
- ACAD $22.10
- MLCO $8.37
- Average True Range (ATR)
- ACAD 0.78
- MLCO 0.42
- MACD
- ACAD 0.08
- MLCO -0.06
- Stochastic Oscillator
- ACAD 58.09
- MLCO 32.45
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts and Entertainment Ltd is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao with the rest largely from the Philippines as of 2024.